Current board rolesCanada's Research-Based Pharmaceutical Companies (Rx&D)
EducationMBA, Henly Management College, United Kingdom
Doctor of Public Health, Columbia University, USA
Master of Public Health, Yale University, USA
Industry affiliationsOntario Health Innovation Council
During Dr. Witek’s 31 year career with Boehringer Ingelheim he held various clinical research positions, including Director of Respiratory and Immunology Clinical Research and most recently he served as President and CEO of Boehringer Ingelheim’s Canadian and Portugese operations.
Dr. Witek is currently Senior Vice President, Corporate Partnerships, Clinical and Medical Affairs at Theravance, Inc. (NASDAQ: THRX). He also serves on the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&D) and is the Chair of the Health Technology Assessment Committee. He was appointed to the Ontario Health Innovation Council and is an Associate Professor at the University of Toronto’s Leslie Dan Faculty of Pharmacy. Dr. Witek is the author of more than 100 scientific papers as well as several chapters and books.
Dr. Witek holds an MBA from Henley Management College in the UK, a Doctor of Public Health from Columbia University and a Master of Public Health from Yale University.